a r t i c l e s The molecular chaperone Hsp90 is an emerging therapeutic target for cancer. Hsp90 promotes the proper folding, assembly and transportation of substrate proteins across cellular compartments 1 . Loss of Hsp90 chaperone activity may result in misfolding of target proteins, ultimately leading to their ubiquitylation and proteasomal degradation 2 . A number of signaling pathway mediators involved in cell growth and survival, as well as aberrant oncogenic fusion proteins, are substrates of Hsp90 and are depleted when tumor cells are exposed to Hsp90 inhibitor drugs 1, [3] [4] [5] [6] .
Because of these activities, several Hsp90 inhibitors are under investigation as anticancer agents 7 . The benzoquinone ansamycin 17-AAG was the first to enter clinical trials; however, its hepatotoxicity and limited solubility and stability led to the development of derivative compounds such as 17-DMAG and IPI-504 (ref. 7) . Side effects remain a concern for these newer ansamycins, because it has not been possible to eliminate the toxic benzoquinone ring without affecting their activity 7 . To avoid these pitfalls, some investigators have designed Hsp90 inhibitors using purine as a scaffold 5, 8 . Optimized water-soluble members of the purine class of Hsp90 inhibitors have recently been synthesized [9] [10] [11] , among which PU-H71 is the most potent compound in its class 12 .
Relatively little is known about the contribution of Hsp90 or the efficacy of Hsp90 inhibitors in the more common types of lymphoid malignancies such as DLBCLs, which are derived from germinal center B cells 13 . The BCL-6 transcriptional repressor is the most frequently involved oncoprotein in DLBCL 14 . The oncogenic effects of BCL-6 are related to its ability to directly repress key genes such as ATR (encoding ataxia telangiectasia and Rad3-related) and TP53 (encoding tumor suppressor protein p53) 15, 16 . In approximately 40% of DLBCLs, constitutive BCL-6 expression is associated with translocations or mutations of its promoter 14 . However, many other DLBCLs express BCL-6 in the absence of genetic lesions, suggesting that other factors can also sustain BCL-6 expression. Regardless of whether the BCL6 locus is mutated, the continued presence of the BCL-6 protein is required to sustain proliferation and survival of DLBCL cells 17, 18 . It was recently shown that Hsp90 is frequently expressed in primary DLBCLs 19 . We hypothesized that sustained BCL-6 expression in DLBCL could be regulated by Hsp90 activity, in which case, Hsp90 inhibition would affect the maintenance of the malignant phenotype by BCL-6.
RESULTS

PU-H71 induces apoptosis in DLBCL cells
To determine the antilymphoma activity of Hsp90 inhibitors, we exposed a panel of DLBCL cell lines to increasing concentrations of PU-H71. DLBCLs can be divided into subtypes with distinct gene expression signatures and responses to drugs and biological agents. One system for dividing DLBCLs classifies them according to their expression of B cell receptor or oxidative phosphorylation genes 20 . A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas We report that heat shock protein 90 (Hsp90) inhibitors selectively kill diffuse large B cell lymphomas (DLBCLs) that depend on the BCL-6 transcriptional repressor. We found that endogenous Hsp90 interacts with BCL-6 in DLBCL cells and can stabilize BCL-6 mRNA and protein. Hsp90 formed a complex with BCL-6 at its target promoters, and Hsp90 inhibitors derepressed BCL-6 target genes. A stable mutant of BCL-6 rescued DLBCL cells from Hsp90 inhibitor-induced apoptosis. BCL-6 and Hsp90 were almost invariantly coexpressed in the nuclei of primary DLBCL cells, suggesting that their interaction is relevant in this disease. We examined the pharmacokinetics, toxicity and efficacy of PU-H71, a recently developed purine-derived Hsp90 inhibitor. PU-H71 preferentially accumulated in lymphomas compared to normal tissues and selectively suppressed BCL-6-dependent DLBCLs in vivo, inducing reactivation of key BCL-6 target genes and apoptosis. PU-H71 also induced cell death in primary human DLBCL specimens. a r t i c l e s The B cell receptor DLBCLs have coordinated repression of Bcl-6 target genes, depend on BCL-6 for their survival 20 and are preferentially sensitive to Bcl-6 targeting by specific peptides 17, 21 and siRNA ( Supplementary Fig. 1) .
In response to PU-H71, BCL-6-dependent DLBCL cell lines showed decreased growth compared to BCL-6 -independent DLBCL cell lines (Fig. 1) . The concentration of PU-H71 that inhibited the growth of the cell lines by 50% compared to control (GI 50 ) in BCL-6dependent DLBCLs was 1.39 µM (±1.00 µM) compared to a GI 50 of 71 µM (±41 µM) in the BCL-6-independent group (P = 0.001, t test) ( Fig. 1a) .
Other features such as abundance of Hsp90-α or Hsp90-β, BCL2 translocation, TP53 mutation status or the activated B cell or germinal center B cell gene expression signatures were not associated with the differential response of these cell lines to Hsp90 inhibition ( Fig. 1b,  Supplementary Fig. 2 and Supplementary Table 1 ). An identical effect was shown with the Hsp90 inhibitor 17-DMAG ( Fig. 1b and Supplementary Table 1 ).
PU-H71 killed DLBCL cells in a dose-dependent manner, preferentially through induction of apoptosis, as shown by nuclear fragmentation observed in ethidium bromide and acridine orange staining, poly-ADP-ribose polymerase (PARP) cleavage and induction of caspase-7 and caspase-3 activity ( Fig. 1c-e ).
Hsp90 maintains the stability of the BCL-6 protein
Because the BCL-6-dependent DLBCL subtype was particularly susceptible to Hsp90 inhibition, we wondered whether BCL-6 might be an Hsp90 substrate protein. We found that a 24-h exposure to PU-H71 induced a dose-dependent reduction in BCL-6 protein abundance in Farage, OCI-Ly7 and SU-DHL4 BCL-6-dependent DLBCL cells ( Fig. 2a) .
PU-H71 also induced the depletion of the known Hsp90 client proteins c-Raf 22 , Akt 23 and NF-κB essential modifier (NEMO) 24 as well as a compensatory increase in Hsp70 (Supplementary Fig. 3a ). In addition, PU-H71 induced a similar pattern of dose-dependent changes in protein abundance, including BCL-6 depletion, in the BCL-6-independent DLBCL cell lines (Toledo, Pfeiffer and Karpas422) ( Supplementary Fig. 3b ).
To determine the kinetics of PU-H71-induced BCL-6 protein depletion, we treated OCI-Ly7 cells with 0.5 µM PU-H71 for 4, 6, 12, 18, 24 and 48 h. After 18 h of treatment, BCL-6 was barely detectable ( Fig. 2b) with two different antibodies for BCL-6 (N3 and C19). PU-H71 accelerated BCL-6 protein decay after protein translation blockade by cycloheximide ( Fig. 2c) . Relative BCL-6 protein abundance decreased from 100% to 50% in 5 h (±1 h) in the presence of PU-H71 compared to 24 h (±2 h) in vehicle-treated cells ( Fig. 2c) . PU-H71-induced downregulation of BCL-6 was also partially blocked by treatment with the proteasome inhibitor bortezomib ( Fig. 2d ).
Hsp90 forms a complex with BCL-6
For BCL-6 to be a direct molecular substrate of Hsp90, the two proteins would need to interact, yet Hsp90 is usually cytoplasmic in normal cells, whereas BCL-6 is localized in the cell nucleus. a r t i c l e s However, Hsp90 was localized to both the cytoplasmic and nuclear fractions of BCL-6-dependent and BCL-6-independent DLBCLs, as well as primary germinal center B cells (centroblasts) ( Fig. 2e) . Moreover, the endogenous BCL-6 and Hsp90 proteins were coimmunoprecipitated from the nuclear fraction of OCI-Ly7 cells (Fig. 2f) . The BCL-6-Hsp90 complex also precipitated in the nuclear fraction of DLBCL cells using PU-H71-coated agarose beads ( Fig. 2f) , indicating that the drug forms a complex with these two interacting proteins.
Protein affinity chromatography experiments using PU-H71-coated agarose beads and in vitro-translated Hsp90 and BCL-6 truncation mutants revealed that it is the middle repression domain of BCL-6 that mediates binding to Hsp90 (Supplementary Fig. 4) .
BCL-6 mediates its biological activity by repressing its target genes, therefore we wondered whether Hsp90 might form part of a promoter-associated BCL-6 repression complex. Quantitative chromosome immunoprecipitation (ChIP) assays revealed the presence of both proteins at each of the six BCL-6 targets examined, including the crucial targets ATR and TP53, as well as ZNF443 (encoding zinc finger protein-443), CD74 (encoding CD74 molecule, major histocompatibility complex, class II invariant chain), CCNI (encoding cyclin I) and TNFAIP8 (encoding tumor necrosis factor, α-induced protein-8) ( Fig. 2g) . Neither protein was present at an upstream region of the TP53 locus nor at the MS4A1 (encoding membrane spanning 4 domains, subfamily A, member 1) promoter. Moreover, the messenger RNA abundance of the BCL-6 target genes ATR, TP53 and CD69 was derepressed by PU-H71 in a time-dependent manner ( Fig. 2h) . Hsp90 may thus function as a corepressor for BCL-6 by maintaining it in a stable conformation directly within BCL-6 repression complexes.
BCL-6 degradation precedes cell death
A marked reduction in BCL-6 protein was evident as soon as 4 h after PU-H71 treatment, before any evidence of cell death ( Supplementary  Fig. 5a ), indicating that BCL-6 degradation induced by PU-H71 precedes cell death. Moreover, exposure of DLBCL cells to a BCL-6 a r t i c l e s peptide inhibitor 17 induced cell death without inducing BCL-6 degradation ( Supplementary Fig. 5b) , showing that BCL-6 degradation does not necessarily accompany apoptosis in DLBCL cells.
To determine whether the sensitivity of BCL-6-dependent DLBCL cells to Hsp90 inhibition was dependent on BCL-6 degradation, we examined whether a proteasome-resistant form of BCL-6 could rescue the actions of PU-H71. We first transfected NIH-3T3 cells with a BCL-6 mutant that is more resistant to proteasomal degradation because it lacks the PEST domain 25 (BCL-6 ∆PEST ), which is located in the middle region of BCL-6. BCL-6 ∆PEST was more resistant to PU-H71-induced degradation than full length BCL-6 (BCL-6 FL ) ( Supplementary Fig. 6a,b) . PU-H71-coated beads also preferentially precipitated BCL-6 FL as compared to BCL-6 ∆PEST (Supplementary  Fig. 6c ). Most notably, transfection of BCL-6 ∆PEST into Farage DLBCL cells more completely rescued the cell killing and caspase-7 and caspase-3 activation effects of PU-H71 compared to transfection of BCL-6 FL (Fig. 2i,j and Supplementary Fig. 6d,e) . A similar effect on cell viability was obtained in SU-DHL6 cells (Fig. 2i) . The data indicate that even though Hsp90 blockade leads to degradation of several proteins, its most therapeutically relevant target protein in the context of DLBCL is BCL-6.
Hsp90 maintains the stability of BCL-6 mRNA
Because a proteasome inhibitor only partially rescued PU-H71 depletion of BCL-6 ( Fig. 2d) , we wondered whether Hsp90 might also block degradation of BCL-6 mRNA. We exposed DLBCL cells to 0.5 µM of PU-H71 for 6, 12 and 24 h and measured BCL-6 mRNA levels by quantitative PCR (qPCR). BCL-6 mRNA levels were reduced in a time-dependent manner at 24 h compared to untreated controls (Fig. 3a) . Exposure of OCI-Ly7 cells to the transcriptional inhibitor actinomycin D in the presence of PU-H71 reduced the half-life of BCL-6 mRNA to 59 min as compared to 87 min in vehicle-treated cells, representing a 32% increase in decay rate (Fig. 3b) .
Heat shock factors can protect certain mRNAs containing AU-rich elements (AREs) in their 3′ untranslated regions 26 , and Hsp90 inhibitors can reduce the stability of certain ARE-containing cytokine transcripts 27 . Analysis of the BCL6 3′ UTR revealed the presence of a putative ARE sequence (AUUUA) between nucleotides 3162 and 3168 (data not shown). The decay of ARE-containing mRNAs can be induced by ARE-binding proteins such as Hsp27 and can be prevented by the p37, p40 and p45 isoforms of AU-rich element RNAbinding protein-1 (AUF1) 26, [28] [29] [30] . Accordingly, PU-H71 increased the a r t i c l e s levels of Hsp27 and decreased the levels of p37, p40 and p45 isoforms of AUF1 in a dose-dependent manner (Fig. 3c) .
Hsp90 and BCL-6 are co-expressed in primary DLBCLs
To determine whether Hsp90 and BCL-6 are co-expressed in primary DLBCLs, we examined a panel of 70 DLBCL cases by immunohistochemistry. Sixty out of 70 (85.7%) individuals expressed high levels of Hsp90, which is similar to the reported incidence of Hsp90 expression 19 . Sixty-one out of 70 (87.1%) cases were positive for BCL-6. Fifty-seven cases (81.4%) were positive for both Hsp90 and BCL-6 ( Fig. 4a) , and there was a strong association between these two proteins (P = 0.00011 by Fisher's exact test).
In DLBCL primary cases, Hsp90 was expressed in both nuclear and cytoplasmic compartments (Fig. 4a) . In addition, we subjected single-cell suspensions from 21 DLBCL biopsy specimens to BCL-6 and Hsp90 immunoblotting. In accordance with the immunohistochemistry data, we found a strong linear correlation between BCL-6 and Hsp90 levels in these samples (r = 0.996, P < 0.00001, Spearman's correlation) (Fig. 4b) . Therefore, co expression of BCL-6 and Hsp90 is physiologically relevant in primary DLBCL tumors.
PU-H71 can kill primary human DLBCL cells
Because PU-H71 is a candidate molecule for the treatment of human lymphomas, and because biological features may differ between cell lines and primary cells, we wished to know whether primary DLBCLs could also respond to this drug. We exposed single-cell suspensions from 21 DLBCL biopsy specimens to 2.5 µM PU-H71 or vehicle control for 48 h. Among the 21 DLBCLs, 19 cases showed greater than 25% loss of viability in response to PU-H71 compared to their respective vehicle-treated controls, indicating that responsiveness to PU-H71 is not limited to cell lines (Fig. 4c) .
Although we detected BCL-6 in all of the cases analyzed (Fig. 4b) , and the majority of the BCL-6-positive DLBCLs are BCL-6 dependent 21 , two cases did not respond to 2.5 µM PU-H71. Additional factors, such as sample heterogeneity and proportion of nontumor cells may also affect the response to the drug.
PU-H71 is preferentially retained in DLBCL xenografts
Hsp90 inhibitors including PU-H71 show preferential uptake in solid tumors compared to normal tissues 6, 7 . To investigate whether a similar effect occurs in DLBCLs, we administered 75 mg per kg body weight PU-H71 intraperitoneally into mice bearing 1-cm 3 Farage, OCI-Ly7 and Toledo DLBCL xenografts. We killed the mice at 6, 12 and 24 h after PU-H71 administration, along with control mice. We analyzed the serum, tumor and normal tissues in Farage and tumor tissues in OCI-Ly7 and Toledo for PU-H71 concentration by HPLC-mass spectrometry. In the Farage mice, PU-H71 was preferentially retained in DLBCLs compared to normal tissues at pharmacologically relevant concentrations at all time points (42.1 µg g −1 at 6 h, 27.6 µg g −1 at 12 h and 12 µg g −1 at 24 h) ( Supplementary Fig. 7) . At 12 h the tumor concentration of PU-H71 was between 11.2 and 125.6 times higher than in normal tissues, and PU-H71 was undetectable in serum after the 6-h time point.
The concentrations of PU-H71 were similar in all of the DLBCL xenografts (Farage, OCI-Ly7 and Toledo), regardless of their response to the drug (Supplementary Fig. 7) . 
PU-H71 potently suppresses DLBCLs in vivo
To determine the efficacy of PU-H71 in vivo, we established Farage, OCI-Ly7 and SU-DHL4 DLBCL xenografts in ten severe combined immunodeficient (SCID) mice each (total n = 30). Once we detected palpable tumors, we randomized pairs of mice to receive either 75 mg per kg body weight per day PU-H71 (n = 5 per cell line) or vehicle (n = 5 per cell line). We killed the mice when two or more controls reached the maximum tumor burden permitted in our mouse protocol. Compared to control, PU-H71 potently lowered DLBCL tumor size and weight (Fig. 5a,b) . The serum concentration of human β2-microglobulin, a marker of tumor burden, was also lowered by PU-H71 (Fig. 5c) . Using tumor growth to critical mass as a measure of survival, we found that PU-H71 (n = 15) significantly prolonged the survival of treated mice compared to controls (n = 15) (Cox's F test, P < 0.0001; Fig. 5d ). In contrast, PU-H71 had no effect on the BCL-6-independent DLBCL Toledo xenografts at a similar dose (Supplementary Fig. 8) .
PU-H71 induced depletion of BCL-6 protein in the tumor xenografts ( Fig. 5e and Supplementary Fig. 9a ) and increased the fraction of cells undergoing apoptosis, as detected by TUNEL assay and PARP cleavage ( Fig. 5f and Supplementary Fig. 9a ). Similar to its effects in vitro, PU-H71 decreased the abundance of c-Raf, Akt and NEMO and induced Hsp70 expression in the DLBCL xenografts ( Fig. 6a and Supplementary  Fig. 9b ). There was no evidence of toxicity from behavioral, macroscopic or microscopic standpoints ( Supplementary  Fig. 10a and data not shown).
Long-term exposure (20 d) to 75 mg per kg body weight per day PU-H71 in OCI-Ly7 xenografts caused significant (P = 0.009) retardation of tumor growth, followed by a steady phase in which the tumors maintained a relatively constant volume of 500 mm 3 (five to six times the initial size) (Supplementary Fig. 11a) . A similar effect was evident with the slow-growing BCL-6-dependent SU-DHL6 xenograft, although these tumors were more completely suppressed and did not grow beyond 100 mm 3 (Supplementary Fig. 11a ). PU-H71 at 75 mg per kg body weight per day was able to decelerate tumor growth in these models, even when the tumors were allowed to reach 500 mm 3 before initiation of treatment (Supplementary Fig. 11b) . Again, there was no evidence of toxicity in these mice (data not shown).
A more extensive toxicity study performed in normal BALB/c mice treated with either 50 mg per kg body weight per d (n = 5) or 75 mg per kg body weight per d (n = 5) of PU-H71 for 10 d (compared to vehicle; n = 5) showed no evidence of macroscopic or microscopic toxicity ( Supplementary Fig. 10b and Supplementary Fig. 12 ). There was also no evidence of hematologic, renal or hepatic toxicity, as determined by complete blood counts, blood chemistry, liver function tests and thyroid hormone testing (since PU-H71 is iodinated) (Supplementary Fig. 10c ).
PU-H71 induces specific changes in gene expression
To further characterize the actions of PU-H71 in DLBCL cells, we administered 75 mg per kg body weight PU-H71 to three pairs of a r t i c l e s Farage xenograft-bearing mice, collected the tumors at 6 and 12 h and performed gene expression profiling compared to vehicle-treated mice. In total, 204 unique genes were downregulated and 79 were upregulated by exposure to PU-H71 ( Fig. 6b, Supplementary Table  2 and Supplementary Fig. 13 ). The list of upregulated genes was enriched for those involved in stress response and proteins containing tetratrico-peptide repeats and apoptosis (Fig. 6b) . Downregulated genes were enriched for chemotaxis and cell cycle regulation (Fig. 6b) . We independently confirmed a number of genes from both lists by qPCR in three cell lines (Farage, OCI-Ly7 and SU-DHL4) at the same time points (6 and 12 h) after 0.5 µM of PU-H71 or control (0 h) (Fig. 6c) .
The proportion of human mRNAs that contain functional AREs has been estimated to be in the vicinity of 8% 31 . Using the same approach, we found that 23.5% (48 of 204) of the downregulated genes and 18.9% (15 of 79) of the upregulated genes contained ARE elements (Supplementary Table 2) , a significant overrepresentation compared to 8% of ARE elements present in the whole array (P < 0.0001 and P = 0.0007 for up-and downregulated genes, respectively, proportion test with continuity correction). BCL6 was among the downregulated ARE-containing genes (Fig. 6b) . Among the upregulated AREcontaining genes, we found 60% (9 of 15) related to the heat shockubiquitin-proteasome pathway ( Supplementary Table 2 ).
To determine whether these effects were common among Hsp90 inhibitors, we queried the Broad Institute connectivity map using the gene set affected by PU-H71. We found high connectivity scores for multiple instances of the four Hsp90 inhibitors present in the database: geldanamycin, 17-AAG, 17-DMAG and monorden (Supplementary Table 3 ). These results suggest that PU-H71, although structurally dissimilar from other Hsp90 inhibitors, induces similar effects.
DISCUSSION
In examining the response of DLBCL cells to Hsp90 inhibitors, we discovered that BCL-6, the most commonly involved oncoprotein in DLBCL, is an Hsp90-chaperoned protein. The relationship between Hsp90 and BCL-6 occurs at multiple levels and has implications for understanding the biology of normal germinal center B cells and DLBCL pathogenesis. Approximately 70% of DLBCLs are BCL-6 positive, yet only about half of these cases contain translocations or point mutations that might drive constitutive BCL-6 expression 14 . But DLBCLs lacking these genetic lesions can still be biologically dependent on this oncogene 17, 18, 21 . The physical and functional interaction of Hsp90 and BCL-6 may at least in part explain this phenomenon, by virtue of directly stabilizing both BCL-6 mRNA and BCL-6 protein. Although the proportional contribution of Hsp90 to BCL-6 mRNA versus BCL-6 protein stability cannot be precisely asserted, our data indicate that both effects contribute to maintain BCL-6 levels. Upregulation of BCL-6 is required for normal B cells to form germinal centers, within which B cells undergo affinity maturation. The fact that Hsp90 localizes to the nucleus of normal centroblasts raises the possibility that it contributes to B cell differentiation by allowing BCL-6 to accumulate in germinal center B cells. These data suggest that BCL6 might, in fact, function as a stress response gene that forms part of a larger, post-transcriptionally regulated program governed by Hsp90.
BCL-6 mediates its transcriptional repressor effect through corepressor recruitment to its target gene promoters 14 . The presence of Hsp90 at BCL-6 target genes may reflect a mechanism whereby Hsp90 maintains BCL-6 stability while it is actively repressing target genes. Hsp90 might have additional roles in BCL-6 repression, for example, by stabilizing other components of the BCL-6 repression complex.
Along these lines, we found that Hsp90 can also bind and stabilize the key BCL-6 corepressor (BCoR) which, like BCL-6, is expressed preferentially in germinal center B cells and in DLBCLs (data not shown). Our data extend the transcriptional regulatory function of Hsp90 that have been uncovered over the years [32] [33] [34] .
The fact that BCL-6 is required for survival of a subtype of DLBCLs is consistent with it being a crucial target of Hsp90 inhibitors in DLBCL, and this scenario was confirmed by experiments showing that a degradation-resistant form of BCL-6 was sufficient to rescue DLBCL cells from the effects of PU-H71. Nonetheless, it is possible that degradation of other Hsp90 substrate proteins could also contribute to some of the activities of Hsp90 inhibitors. For example, it has been shown that avian B cells depleted of Hsp90 showed defective B cell receptor signaling 35 . A detailed examination of the B cell receptor pathway in DLBCL cells might thus yield additional targets of interest. A recent report also showed that Akt can be a target of Hsp90 in DLBCL cells 36 .
From the therapeutic standpoint, it is imperative to identify drugs that can improve the efficacy and reduce the toxicity of standard antilymphoma therapy. Our data show that Hsp90 inhibitors preferentially accumulate within lymphomas to a much greater extent and duration than in normal tissues. Moreover, PU-H71 is a remarkably potent and well-tolerated antilymphoma agent in vivo. The ability of PU-H71 to facilitate the derepression of BCL-6 target genes involved in DNA damage checkpoints suggests that these drugs might enhance the cytotoxic effects of chemotherapy drugs, and it has been shown that 17-DMAG can, in fact, induce such an effect in several lymphoid cell lines (including DLBCLs) 37 . Taken together, this study demonstrates, and describes the mechanistic basis for, the efficacy of therapeutic targeting of DLBCLs with Hsp90 inhibitors and provides a rationale for the initiation of clinical trials of PU-H71 for individuals with BCL-6-dependent DLBCLs.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/. Accession numbers. Expression profiling data have been deposited in Gene Expression Omnibus (GEO) and are accessible through GEO series accession number GSE13401.
Note: Supplementary information is available on the Nature Medicine website.
